Boston Scientific Appoints Cathy Smith and Christophe Weber to Boost Leadership and Innovation

Strategic Leadership Changes at Boston Scientific: Enhancing Innovation and Growth

Boston Scientific Corporation recently announces the election of Cathy Smith and Christophe Weber to its Board of Directors, effective February 18, 2026. This significant development is part of a broader strategy to enhance the company’s leadership team and drive innovation in medical technology. Smith, who serves as the chief financial officer of Starbucks, brings extensive expertise in finance and strategic operations. Her impressive background includes leadership roles at major companies such as Nordstrom, Target, and Walmart, along with significant board experience at PPG Industries. With advanced degrees in business and economics, she is well-positioned to contribute to Boston Scientific’s financial strategies and operational efficiencies.

Christophe Weber, who has been president and CEO of Takeda Pharmaceutical, adds a powerful pharmaceutical perspective to the board. With a strong foundation in global pharmaceutical leadership and extensive experience in operations at GlaxoSmithKline, Weber's insights are expected to be valuable as Boston Scientific expands its therapeutic offerings. His educational background, including a doctorate in pharmacy and degrees in accounting and finance, aligns with the company’s goals of advancing complex medical solutions. Both Smith and Weber are seen as instrumental in supporting Boston Scientific’s mission to innovate and improve patient care, particularly as the company seeks to address pressing healthcare needs globally.

According to Boston Scientific’s chairman and CEO Mike Mahoney, these new board members bring “deep leadership, strategic insight, and a track record of value creation” that will significantly aid in driving the company’s innovation and growth initiatives. Their appointments come as the company prepares for a transition following the retirements of directors John Sununu and Yoshiaki Fujimori, who will not seek re-election at the upcoming annual meeting. Leadership continuity and strategic vision remain paramount as Boston Scientific seeks to navigate the complex landscape of medical technologies, ensuring it remains at the forefront of patient care advancements.

In related news, Boston Scientific continues to leverage its extensive portfolio of medical devices and therapies across various specialties, including cardiovascular and neurological conditions. The company remains committed to reducing healthcare costs while enabling healthcare providers to deliver high-quality care globally. This renewed governance structure aims to bolster its capabilities in addressing unmet medical needs effectively and efficiently.